Introduction
Thyroid follicular cells accumulate iodide, which is used for radioiodine therapy in benign thyroid diseases as well as for therapy of differentiated thyroid carcinoma. The first step in the complex process of iodide trapping in the thyroid is the active transport of iodide together with sodium ions into the cell, which is mediated by the sodium-iodide symporter. This process against an electrochemical gradient requires energy, is coupled to the action of Na + /K + -ATPase and is also stimulated by TSH. [1] [2] [3] [4] [5] Since the cloning of the human and rat cDNA sequences several experimental studies have been performed, which investigated the recombinant expression of the hNIS gene in malignant tumors by viral transfer of the hNIS gene under the control of different promoter elements. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Although all of them reported high initial uptake in the genetically modified tumors, differing results have been obtained concerning the efficiency of radioiodine treatment based on NIS gene transfer with generally very high doses given to tumorbearing mice. In this study, we used the gene for the human sodium-iodide symporter as a paradigm for the genetically modified uptake of 131 I in a rat prostate carcinoma model, and evaluated the iodide uptake kinetics and dosimetry after doses that are commonly administered to patients.
Results

Immunocytochemistry
Immunocytochemistry using two different clones of anti-NIS antibodies (BrA 6-1 and BrA 10-11) revealed a strong red fluorescence (Cy3) on the cell surface of hNIS expressing AT1 cells, whereas nontransfected cells (wild-type AT1) showed no NIS immunoreactivity neither using anti-NIS antibodies of the clone BrA 6-1 nor of the clone BrA 10-11 (not shown). Omission of the primary antibody abolished the immunoreactivity completely. À incubation was at a plateau level implicating the steady-state uptake.
A functional characterization of the cells was performed by competition and efflux experiments. Figure 2 presents the effect of DIDS, FCCP, sodium perchlorate and ouabain on the Na 125 I uptake in the wild-type (a) and the hNIS (b) expressing cells. In the presence of 10 or 50 mM sodium perchlorate, we observed a dose-dependent inhibition of iodide accumulation in the AThNIShygg cells, which was 89.9 and 94.5%, respectively. Ouabain caused a 94.2% inhibition in uptake. The addition of the proton conductor FCCP led to a loss of 82.1% of the accumulated I À . The anion channel blocker DIDS had an opposite effect, as it increased the I À uptake into the cells to 136% at a concentration of 300 mM and 115% with 100 mM (Figure 3) .
In order to evaluate iodide efflux 125 I uptake was allowed to proceed for 1 h, at which time a steady-state level of iodide accumulation was achieved. After the medium had been replaced by nonradioactive medium, the amount of 125 I À present in the AThNIShyg9 cell lysates was determined as a function of time. Up to 59% of the cellular radioactivity was released into the medium after 10 min and 81% efflux was observed after 20 min, indicating that the radiotracer was not trapped in the recombinant prostate carcinoma cells (Figure 3 ). The addition of 300 mM DIDS to the culture led to an increase of the initial 125 I À uptake; however, a prolonged intracellular retention of the tracer was not achieved.
Iodide uptake in tumor-bearing rats
To investigate the iodide uptake in hNIS expressing or nonexpressing Dunning prostate adenocarcinoma in vivo AThNIShyg9 cells or wild-type AT1 cells were transplanted into the right and left high of male young adult Copenhagen rats. After the animals had been injected with 131 I À , a dynamic scintigraphic image was taken to evaluate radioactivity in the blood circulation, the tumor tissue and in different organs. Consistent with the data obtained from the in vitro studies the hNIS-expressing tumor tissue significantly accumulated 131 I À leading to scintigraphic visualization, whereas only low-iodide uptake was observed in the wild-type prostate carcinoma ( Figure 4 ). In the genetically modified tumor, the tracer accumulation increased to a maximum level during the first hour after administration, followed by a decrease of the intratumoral radioactivity ( Figure 5 and Table 1 
Discussion
Currently used viral vectors for gene therapy of cancer have a low infection efficiency leading to moderate or low therapy effects. This problem could be solved using an approach that leads to accumulation of radioactive isotopes with beta emission. In this case, isotope trapping centers in the tumor could create a crossfiring of beta particles thereby efficiently killing transduced and nontransduced tumor cells. Transfer of the hNIS gene in rat prostate carcinoma U Haberkorn et al tumors. NIS gene transfer resulted in a high uptake in a variety of tumor models. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In the rat prostate carcinoma we observed an up to 200-fold increased uptake as compared to the wild-type cell line which is similar to values reported in other models. 8, 10, 12, 13 However, as observed in a previous study with a rat hepatoma a rapid efflux occurred with 81% of the radioactivity released into the medium after 20 min. Similar data have been obtained by other groups in different tumor models. 12, 15, 17, 18, 21 Since the effectiveness of radioiodine therapy depends not only on the type and amount, but also on the biological half-life of the isotope in the tumor, a therapeutically useful absorbed dose seems unlikely for that type of experiments.
A significant efflux was also seen in vivo: only 0.470.2 (1200 MBq/m 2 ) and 0.2470.02% (2400 MBq/m 2 ) of the injected dose per g in the hNIS-expressing tumors were observed at 24 h after tracer administration. Similarly, Nakamoto et al found less than 1% of the injected radioactivity at 24 h after 131 I administration in modified MCF7 mammary carcinomas, although initially a high uptake was seen. 15 This corresponds to a very short halflife of 131 I (7.5, 7.3 or 9.0 h) in rat prostate carcinomas, which has also been described by Nakamoto et al 15 for human mammary carcinomas with a calculated biological half-life of 3.6 h. In contrast, differentiated thyroid carcinoma showed a biological half-life of less than 10 d and normal thyroid of approximately 60 d. 22 However, in vitro clonogenic assays revealed selective killing of NIS-expressing cells in some studies. [8] [9] [10] 14, 19 The activities applied were 29.6 MBq for 7 h, 3.7 MBq for 7 h or 4 MBq/ml. 19, 14, 10 Also, bystander effects have been suggested in three-dimensional spheroid cultures. 10 In vivo experiments in stably transfected human prostate carcinoma cells revealed a long biological half-life of 45 h. 19 This resulted in a significant tumor reduction (84712%) after a single intraperitoneal application of a very high 131 I dose of 111 MBq. 19, 20 In order to improve therapy outcome, Smit et al investigated the effects of low-iodide diets and thyroid ablation on iodide kinetics. 18 The half-life in NIS-expressing human folliculary thyroid carcinomas without thyroid ablation and under a regular diet was very short with 3.8 h. In thyroid-ablated mice kept on a low-iodide diet, half-life Our study investigated the absorbed dose in genetically modified tumors after treatment with amounts of 131 I corresponding to those given to patients. In order to determine the administered doses to the rats, we used factors relating the body weight to the body surface as described by Freireich et , which resulted in only 3 Gy absorbed dose in the genetically modified tumors. Since approximately 80 Gy has been described as necessary to achieve elimination of metastases in patients with thyroid cancer, this is not likely to induce a significant therapeutic effect in the tumors. 24 Furthermore, the experiments were performed under ideal conditions with 100% NIS-expressing cells in the tumors. Given the low infection efficiency of currently viral vectors in vivo, the absorbed dose in a clinical study would be considerably lower.
There are several differences between our study and the experiments of Spitzweg and Smit: administered dose, mode of 131 I application and the tumor and animal systems used. [17] [18] [19] [20] In a mouse, doses of 74 and 111 MBq correspond to administered doses of 11 100 and 16 650 MBq/m 2 , respectively. This is far more than the doses used in patients. There is also a difference in tracer administration: intraperitoneal or subcutaneous versus intravenously. Intraperitoneal or subcutaneous administration may result in prolonged retention in the animal because of prolonged resorbtion, which may partly explain the longer half-life observed in these studies. Furthermore, Smit et al injected 131 I at 3 weeks after transplantation when tumors were not visible. Tumors of small size may have a better chance to respond because there are no hypoperfused regions with limited tracer availability. However, this is not a realistic simulation of the tumor patient. There are also differences in the animal and tumor models, which may explain the varying results: Spitzweg et al and Smit et al used human tumors in nude mice, we used a syngeneic rat model. Therefore, differences in the biodistribution of iodide and the biochemical properties of the tumor cells may lead to differences in iodide retention. However, Smit et al observed similar values in tumor-bearing mice with intact thyroids. Finally, it is possible that thyroid ablation as described by Smit et al would also result in a longer intratumoral half-life of iodide in our tumor model. Mean values and standard deviation (n=4). The weight represents the weight of the tissue sample measured including blood.
Transfer of the hNIS gene in rat prostate carcinoma U Haberkorn et al
In order to prolong the iodine retention time in tumors some authors tried to simultaneously transfer the NIS and the thyroperoxidase gene.
9, 21 Boland et al observed iodide organification in cells coinfected with both the NIS and the TPO gene in the presence of exogenous hydrogen peroxide. However, the levels of iodide organification obtained were too low to significantly increase the iodide retention time. In a variety of different cell lines including human anaplastic thyroid carcinoma and rat hepatoma cells, we were not able to measure TPO enzyme activity or enhanced accumulation of iodide irrespective of very high amounts of hTPO protein after retroviral transfer of the human TPO gene. 25 In contrast, Huang et al observed an increased radioiodide uptake (by a factor of 2.5) and retention (by a factor of 3) and enhanced tumor cell apoptosis after transfection of nonsmall cell lung cancer cells with both human NIS and TPO genes. 21 However, a 72% efflux occurred in vitro during the first 30 min, indicating a very low hTPO activity in the genetically modified cells. Therefore, other modulations of iodide retention in tumor cells should be evaluated in future studies. The determinants of TPO activity are incorporation of a heme prosthetic group, glycosylation, localization, conformation, multimerization of the protein and the presence of thyroglobulin as acceptor. Therefore, future approaches in our laboratory are directed towards stabilization of TPO by cotransfer of calreticulin and also the induction of thyroid specific gene expression by transfer of thyroidspecific transcription factors. Alternatively, we are using other peroxidases such as myeloperoxidase and lactoperoxidase.
Lithium has been reported to reduce the release of iodine from the thyroid and, therefore, was used to enhance the efficacy of radioiodine treatment of differentiated thyroid cancer. 26 When the biological half-life was less than 3 days lithium prolonged the effective halflife by more than 50%. 26 In FRTL-5 rat thyroid cells and in primary cultures of porcine thyroid follicles 2 mM lithium suppressed TSH-induced iodide uptake, iodide uptake stimulated by 8-bromo-cAMP, iodine organification and de novo thyroid hormone formation. 27, 28 Lithium is concentrated by the thyroid and inhibits thyroidal iodine uptake, iodotyrosine coupling, alters thyroglobulin structure and inhibits thyroid hormone secretion. [27] [28] [29] [30] [31] Therefore, if enhanced iodide trapping in the thyroid by lithium relies on interaction with iodine coupling to tyrosine residues or inhibition of thyroid hormone secretion, an organification process is still needed to obtain a sufficient iodine accumulation in the tumor. First experiments in our laboratory showed only a marginal effect of lithium in hNIS-expressing hepatoma cells. 32 A further option to increase therapy outcome is the use of biologically more effective isotopes. Dadachova et al I for the treatment of NIS-expressing mammary tumors. 33 In a xenografted breast cancer model in nude mice, 188 Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry showed that 188 Re-perrhenate delivered a 4.5 times higher dose than 131 I and, therefore, may provide enhanced therapeutic efficacy. Furthermore, the high LET -emitter astatine-211 has been suggested as an isotope with high radiobiologic effectiveness. 15, 34 First experiments showed that the tracer uptake in NISexpressing cell lines increased up to 350-fold for 123 At. Although all radioisotopes showed a rapid efflux, higher absorbed doses in the tumor were found for 211 At as compared to 131 I. 34 In conclusion, transfer of the sodium-iodide transporter gene into rat prostate adenocarcinoma cells together with the application of 131 I in clinically relevant amounts did not result in therapeutically useful absorbed doses in the NIS-expressing tumors in vivo. Further studies have to examine pharmacological modulation of iodide efflux or the use of the hNIS gene as an in vivo reporter gene. 35 
Materials and methods
Retroviral transfer of the hNIS gene
For transfer of the hNIS gene a bicistronic retroviral vector was used consisting of the hNIS gene and the hygromycin resistance gene cloned downstream of the elongation factor 1a (EF1a) promoter. To ensure simultaneous expression of the genes coding for the hNIS and for the hygromycin resistance and stabilization of the mRNA, a synthetic intron and an internal ribosomal entry site from encephalomyocarditis virus (EMCV) were inserted between the genes. 12 
Cell culture, retroviral infection and generation of recombinant cell lines
The rat prostate adenocarcinoma cell line (Dunning R3327 subline AT1) and the transient packaging cell line BOSC23 employed for the production of ecotropic retroviral particles were cultured in RPMI1640 medium (Gibco BRL, Eggenstein, Germany) supplemented with 292 mg/l glutamine, 100 000 IE/l penicillin, 100 mg/l streptomycin and 10% fetal calf serum. 12, 36 The cell lines were cultured at 37 1 C, in an atmosphere of 95% air and 5% CO 2 .
For transient packaging of the retroviral particles a lipofection of BOSC23 cells was carried out. After 2 days the medium was centrifuged to remove detached BOSC23 cells and used for the infection of the AT1 cells in the presence of 8 mg polybrene/ml overnight. The cells were treated with 425 mg/ml hygromycin for 4 weeks until 16 resistent cell lines were established. These were used in iodide uptake experiments. The cell line which presented the maximal 125 I À uptake (AThNIShyg9) was employed for the following experiments. The tumor doubling time in vitro was 11.271.3 h for AT1 and 12.471.4 h for AT1NIShyg9.
Immunocytochemistry
Immunocytochemistry was performed according to the procedures previously described with minor modifications. 37 In detail, cells were fixed with 2% formaldehyde in 10 mM PBS (20 min, on ice) and 0.2% Triton X-100 in PBS (10 min, room temperature [RT]). For immunostaining monoclonal mouse anti-human sodium-iodide symporter antibodies BrA 6-1 and BrA 10-11 with 80 mg/ml in PBS for 1 h at RT (BRAHMS Diagnostics, Berlin, Germany) were used. After exposure to these antibodies, the cells were incubated with Cy3-conjugated goat anti-mouse IgG (1:100, 1 h, RT; Dianova, Hamburg, Germany). Finally, nuclei were counterstained with Hoechst 33342 dye (1 mM; Molecular Probes, Leiden, Transfer of the hNIS gene in rat prostate carcinoma U Haberkorn et al
The Netherlands). After every incubation period rinsing steps (three times, 5 min; RT) with 10 mM PBS were included. As a negative control, the primary antibody was omitted. Cells were analyzed and photographed using an Axiophot fluorescence microscope (Zeiss GmbH, Jena, Germany). Digitalized figures were processed, arranged and lettered by computer software (Adobe Photoshop 5.0/Illustrator 8.0).
Measurement and modulation of the
I uptake and efflux
The iodide uptake was determined in triplicates as described previously. 2, 12 In the presence of 74 kBq Na 125 Iodide (Amersham Buchler Germany; specific activity 625.3 MBq/mg; radioactive concentration 3.7 GBq/ml; radiochemical purity 99.3%) the recombinant cell line AT1hNIShyg9 and wild-type AT1 cells were cultured for 1, 2, 5, 10, 30 min, or 1, 2 and 4 h in six-well plates. In order to simulate the clinical situation of radioiodine treatment, we added no cold NaI. After washing twice with ice-cold phosphate-buffered saline (PBS), the cells were lysed with sodium hydroxide on ice. Using an automated NaI(Tl) well counter (Cobra II, Canberra Packard, Meriden, CT, USA) the radioactivity was measured in cell lysates and in the medium. The viable cell number was determined in a Coulter counter (Coulter Electronics, Dunstable, UK) and by trypan blue staining (more than 94% viable cells). Using the Coulter counter a median cell volume of 1.3 fl (between 0.6 and 3.1 fl) with no significant difference for the genetically modified and wild-type AT1 cells was measured.
For the modulation of the iodide uptake hNISexpressing and wild-type cells were incubated for 1 h in Na 125 I medium (74 kBq) or Na 125 I-medium supplemented with 10 or 50 mM sodium perchlorate (SigmaAldrich, Taufkirchen, Germany), 0.5 mM ouabain, 100 or 300 mM of the anion channel blocker 4,4 0 -diisothiocyano-2,2 0 -disulfonic acid stilbene (DIDS; Sigma-Aldrich) or 10 mM of the proton conductor carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP; Sigma-Aldrich) according to Weiss et al. 2 Thereafter, the cells were washed, lysed and counted as described.
To determine the 125 Iodide efflux recombinant and wild-type cells were incubated for 1 h in the presence or absence of 300 mM DIDS with a medium containing 74 kBq Na 125 Iodide in six-well plates. After the cells had been washed twice three wells were lysed immediately. To the other wells fresh nonradioactive medium was added and the cells were again incubated for 2, 4, 6, 8, 10, 12, 16 or 20 min, and washed and lysed as described.
Measurement of the 131 I uptake in tumor tissue of rats
The experiments were performed in compliance with German laws relating to the conduct of animal experimentation. 2.5 Â 10 6 tumor cells in 100 ml were transplanted subcutaneously into the right (AT1hNIShyg9) or left (wild-type AT1) thigh of male young adult Copenhagen rats weighing 268.1729.8 g. For imaging studies that were performed under general gaseous anesthesia (40% O 2 ) into the lateral tail vein of the rats a dynamic scintigraphic image was taken for the following 30 min to evaluate the early tumor uptake and the resulting body distribution of 131 I using a 10 in scintillation-camera (Searle-Siemens, Germany). The time-dependent relative accumulation of radioactivity in different regions of interest (ROI), for example, the heart, the liver, the tumor, the bladder and the whole animal was monitored in six animals at 1, 2, 4, 8 and 24 h postinjection.
The dose given to the animals was determined using the formula injected dose per rat ¼ ðdose per m 2 =FÞ Ã body weight of the rat in kg where F is a weight-dependent factor that was taken according to Freireich. 23 The F values for a 150, 200 or 250 g weighing rat are 5.9, 6.5 and 7, respectively (F¼3 for mice and F¼37 for patients).
The absolute amount of radioactivity (% injected dose/ g wet tissue) was determined in 20 animals after 1200 and 2400 MBq/m ) postinjection to analyze the tumors using an automated NaI(Tl) well counter (Cobra II, Canberra Packard, Meriden, CT, USA). Using MIRDOSE 3* 38 the cumulated activity and the absorbed dose in wild-type and hNIS-expressing tumors after administration of 1200 and 2400 MBq/m 2 131 I was calculated for a unit density sphere with a mass of 1 g considering only the value of the absorbed dose in the sphere. Therefore, the sum of two exponential decay functions was fitted to the data points. The MIRDOSE3 calculation S-value for self-irradiation was 29.5 mGy/MBq s.
